Hematuria Treatment Market Size, Trends and Growth Analysis by 2027

The hematuria treatment market is anticipated to grow significantly, reaching an estimated US$ 1,103.61 million by 2028, up from US$ 932.89 million in 2021. This growth represents a compound annual growth rate (CAGR) of 2.4% from 2020 to 2028.

Several factors are contributing to the expansion of this market. The high incidence of conditions associated with hematuria, along with a rising awareness of available treatment options and increasing healthcare spending, are key drivers of market growth. However, the presence of undiagnosed cases related to these conditions poses a challenge, potentially limiting the effectiveness of hematuria treatments and hindering overall market progress.

In the Asia-Pacific (APAC) region, the hematuria treatment market is experiencing rapid growth. The COVID-19 pandemic led to various government-imposed restrictions that affected ongoing clinical research. Nevertheless, as these restrictions are gradually lifted, research activities are picking up pace, which is expected to enhance the demand for hematuria treatments in the near future.

The hematuria treatment market can be categorized based on treatment types, indications, types of hematuria, and end users. In terms of treatment, the market is divided into drugs, therapies, and others. The drugs and therapies segment is projected to hold the largest market share in 2020 and is also expected to exhibit the highest CAGR throughout the forecast period from 2020 to 2028.

When examining the market by indication, it is segmented into various conditions such as urinary tract infections, kidney stones, urethritis, blood cancer, bladder stones, prostate cancer, cystitis, trauma, vigorous exercise, polycystic kidney disease, endometriosis, and menstruation. The urinary tract infections segment was the market leader in 2020, accounting for 17.31% of the market share, and it is expected to maintain its leading position throughout the forecast period.

Additionally, the hematuria treatment market is classified by type into macroscopic hematuria, microscopic hematuria, idiopathic hematuria, and jogger's hematuria. The microscopic hematuria segment is projected to capture the largest market share in 2021, while the macroscopic hematuria segment is expected to grow at a CAGR of 2.6% during the forecast period.

From an end-user perspective, the hematuria treatment market is further divided into hospitals, clinics, ambulatory surgical centers (ASCs), and others. The hospital segment dominated the market in 2020, holding a share of 36.52%, and is anticipated to continue its dominance in the coming years.

In preparing the report on the hematuria treatment market, various primary and secondary sources were consulted, including reputable organizations such as the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and the International Society for Stem Cell Application.

In conclusion, the hematuria treatment market is poised for growth driven by increasing awareness, healthcare expenditure, and the prevalence of related conditions. Despite challenges posed by undiagnosed cases and the impact of the COVID-19 pandemic on research, the market is expected to rebound and expand, particularly in the APAC region.